Alpha Tau Medical stock gets an October 15 conference date

Alpha Tau Medical stock (ISIN IL0011839383) was last at USD 14.25 on Nasdaq on October 7, 2026, down 1.59 percent from the prior close. The company has set October 15, 2026, for a presentation at the Investment Generation Conference in Israel.

October 15 brings the next checkpoint

StockTitan reported on October 5, 2026, that Alpha Tau management would hold a presentation at the Investment Generation Conference on October 15 from 12:30 p.m. to 1:00 p.m. local time in Rishon Letzion, Israel.

The date gives investors a near-term corporate checkpoint, but it is a presentation rather than a newly announced clinical readout or financial result. Alpha Tau is developing Alpha DaRT, an intratumoral alpha-emitting radiotherapeutic for solid tumors, including pancreatic, skin, head and neck, brain, prostate, lung and liver cancers.

Q2 loss included a warrant effect

Alpha Tau reported a Q2 2026 net loss of USD 45.8 million, or USD 0.50 per diluted share. Investing.com said the loss exceeded H.C. Wainwright's USD 12.4 million estimate, primarily because of a revaluation of the warrant liability.

The comparison matters because the reported loss was not solely a measure of recurring research spending. Alpha Tau remains a clinical-stage company, so trial expansion and regulatory progress carry more weight than commercial revenue in the current investment case.

Target stands above the Nasdaq price

Investing.com reported that H.C. Wainwright maintained a Buy rating while raising its price target to USD 16 from USD 15. The USD 16 target lies 12.3 percent above the USD 14.25 Nasdaq price.

Alpha Tau's share price remains below its 52-week high of USD 15.79 and above its 52-week low of USD 3.43. The current market capitalization is USD 1.3 billion, while October 7 volume reached 466,256 shares.

Nasdaq stock stays below its yearly high

For investors, the October 15 presentation and the warrant-related Q2 loss frame the next discussion around clinical execution and financing discipline. Alpha Tau's treatment platform is designed to place radium-224 sources directly inside tumors, with the company evaluating the approach across several solid-tumor indications.

Alpha Tau Medical stock was last at USD 14.25 on Nasdaq on October 7, 2026, at 3:12 p.m. ET. The stock's 52-week range was USD 3.43 to USD 15.79.

Upcoming dates for Alpha Tau Medical stock

• October 15, 2026: Investment Generation Conference presentation

More news and analyses on Alpha Tau Medical stock